Navigation Links
ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
Date:11/8/2011

hile demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetics, and is now in Phase II clinical development for the treatment of diabetic nephropathy. Other clinical programs include CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR inhibitor, in Phase II clinical development for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis; and CCX832, a ChemR23 antagonist in Phase I clinical development. ChemoCentryx also has several programs in advanced preclinical development.

Certain statements in this press release may constitute "forward-looking statements". These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy or actual results to differ materially from those expressed or implied. We do not intend, and undertake no obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.Contacts:Susan M. Kanaya

Burns McClellanSenior Vice President, Finance and

Media InquiriesChief Financial Officer or

Kathy Nugent, Ph.D.Markus J. Cappel, Ph.D.

212-213-0006Chief Business Officer

knugent@burnsmc.com650-210-2900investor@chemocentryx.com
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
2. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
3. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
4. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
6. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
7. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
10. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
11. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
(Date:1/15/2014)... Sono-Tek Corporation (OTC BB: SOTK) today announced sales of  ... to sales of $2,202,000 for the prior year period, an ... also shown growth over the preceding quarter,s sales, continuing a ... year. Markets that experienced sales increases over the prior year ...
(Date:1/15/2014)... Mich. , Jan. 15, 2014 As health officials ... flu virus, select Meijer pharmacies in Michigan ... throat to eligible patients, enabling Meijer pharmacists to administer tests ... protocol set by a physician participating in the study. ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
... Feb. 21, 2012 ConvaTec, a world-leading developer and ... care, today announces that Ken Berger will assume the ... the ConvaTec Board of Directors. Berger joins ... last ten years, most recently as Senior Vice President ...
... Feb. 21, 2012  Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX ... overview at the Citi Global Healthcare Conference on February 27, ... New York City.   The live and archived ... of Events" in the Idenix Investor Center at ...
Cached Medicine Technology:ConvaTec Announces the Appointment of Ken Berger to the Position of CEO Effective March 6, 2012 2
(Date:7/11/2014)... disposable medical suppliers call for the biggest share of ... past two decades, the world market for disposable medical ... year), primarily owing to the importance of these products ... market for disposable medical supplies in the world, accounting ... held by Europe with a 29% market share. The ...
(Date:7/11/2014)... July 11, 2014 The Corn ... years to 2014 on the heels of fresh biofuel ... farmers to dedicate a larger share of their farmland ... specifically, the regulations required the mixing of 5.0% renewable ... production in the United States created a key export ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Ticket Down ... Tickets at the Sleep Train Amphitheatre in Wheatland, CA. ... that can compare to what the Sleep Train Amphitheatre can ... events and special attractions over the course of its existence ... the Sleep Train Amphitheatre in Wheatland (Sacramento metro area) will ...
(Date:7/11/2014)... are insoluble colorants, which usually consist of inorganic compounds. ... and coloring. These are water and oil insoluble natural ... as paper, paints, plastics, and concrete. Binders are used ... to the substance. Some examples of pigments are titanium ... coloring action of pigments is due to the scattering ...
(Date:7/11/2014)... With the arrival of summer, VisitandCare.com today ... and hair transplant procedures, up 80 percent from July ... medical tourism destinations, the company is helping patients take ... achieve the look they have always desired. , ... in the medical tourism industry, VisitandCare.com is comprised of ...
Breaking Medicine News(10 mins):Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 3
... 11 /PRNewswire-FirstCall/ - BELLUS Health Inc. ("BELLUS Health" or ... quarter and first half ended June 30, 2009. All ... US dollars, unless otherwise specified. , For the three-month ... to $12,880,000 ($0.10 per share), compared to a net ...
... Illinois at Chicago College of Medicine researchers have discovered how ... may lead to a more effectively targeted anti-cancer strategy. ... PLoS ONE online, UIC researchers show how a class ... the drugs, ability to inhibit FoxM1 may account for their ...
... WEST PALM BEACH, Fla., Aug. 11 HearUSA (Amex: EAR ... ring aids and hearing care announced today that it is launching ... The program is scheduled to be made available to AARP members in Florida ... in all 50 states and the U.S. territories. , , ...
... , OKLAHOMA CITY, Aug. 11 ... for revenue cycle management solutions for the healthcare industry, ... Financial Services Accreditation Program (FSAP) - Electronic Health Network ... EHNAC FSAP-EHN accreditation demonstrates that the organization meets a ...
... , PALO ALTO, Calif., Aug. 11 Jazz Pharmaceuticals, Inc. ... quarter ended June 30, 2009. , , Total revenues ... the quarter ended June 30, 2008. Revenues for the second quarter included ... in July 2008 and recognized as revenue when the last patient completed ...
... , LAKEWOOD, Colo., Aug. 11 Mesa Laboratories, Inc. ... Directors has declared a regular quarterly cash dividend of 10 cents ... shareholders of record at the close of business on August 28, ... and markets electronic instruments and disposables for industrial, pharmaceutical and medical ...
Cached Medicine News:Health News:BELLUS Health reports results for first half of fiscal 2009 2Health News:BELLUS Health reports results for first half of fiscal 2009 3Health News:BELLUS Health reports results for first half of fiscal 2009 4Health News:BELLUS Health reports results for first half of fiscal 2009 5Health News:BELLUS Health reports results for first half of fiscal 2009 6Health News:BELLUS Health reports results for first half of fiscal 2009 7Health News:BELLUS Health reports results for first half of fiscal 2009 8Health News:BELLUS Health reports results for first half of fiscal 2009 9Health News:BELLUS Health reports results for first half of fiscal 2009 10Health News:BELLUS Health reports results for first half of fiscal 2009 11Health News:BELLUS Health reports results for first half of fiscal 2009 12Health News:BELLUS Health reports results for first half of fiscal 2009 13Health News:BELLUS Health reports results for first half of fiscal 2009 14Health News:BELLUS Health reports results for first half of fiscal 2009 15Health News:BELLUS Health reports results for first half of fiscal 2009 16Health News:BELLUS Health reports results for first half of fiscal 2009 17Health News:BELLUS Health reports results for first half of fiscal 2009 18Health News:BELLUS Health reports results for first half of fiscal 2009 19Health News:BELLUS Health reports results for first half of fiscal 2009 20Health News:BELLUS Health reports results for first half of fiscal 2009 21Health News:BELLUS Health reports results for first half of fiscal 2009 22Health News:BELLUS Health reports results for first half of fiscal 2009 23Health News:BELLUS Health reports results for first half of fiscal 2009 24Health News:BELLUS Health reports results for first half of fiscal 2009 25Health News:BELLUS Health reports results for first half of fiscal 2009 26Health News:BELLUS Health reports results for first half of fiscal 2009 27Health News:BELLUS Health reports results for first half of fiscal 2009 28Health News:Finding may explain anti-cancer activity of thiazole antibiotics 2Health News:HearUSA Makes Hearing Aids and Care Available to AARP Members 2Health News:HearUSA Makes Hearing Aids and Care Available to AARP Members 3Health News:HearUSA Makes Hearing Aids and Care Available to AARP Members 4Health News:Revenue Management Solutions, LLC Receives EHNAC Financial Services Accreditation 2Health News:Revenue Management Solutions, LLC Receives EHNAC Financial Services Accreditation 3Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 2Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 3
... meridianEMR is a revolutionary "blended model ... patient medical records in your office and ... team of physicians and software engineers, meridianEMR ... to create a highly modular medical EMR ...
... OB/GYN, ER/Trauma, ICC/CCU, woundcare and burn ... precision and control, plus consistent high ... SATIN PLUS* Sterile Singles deliver all ... provides excellent tactile sensitivity. The gloves ...
... Polymed has become even better. Polymed® TLC latex ... Polymed with the exciting addition of vitamin E. ... which are vital to healthy skin. Polymed TLC ... reduce the potential for latex sensitization. The lightly ...
... Clear View Drapes allow practitioners ... patient's leg during intraoperative adjustments. Makes ... and access legholder adjustment handles for ... tear even when controls are adjusted ...
Medicine Products: